FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

AIM: To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma. METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Gastroenterol
Main Authors: Guion-Dusserre, Jean-Florian, Lorgis, Veronique, Vincent, Julie, Bengrine, Leila, Ghiringhelli, Francois
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Inc 2015
Assuntos:
Retrospective Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326145/
https://ncbi.nlm.nih.gov/pubmed/25717243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i7.2096
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados